Last reviewed · How we verify

PA5108 Latanoprost FA SR Ocular Implant

PolyActiva Pty Ltd · Phase 1 active Small molecule

PA5108 Latanoprost FA SR Ocular Implant is a Small molecule drug developed by PolyActiva Pty Ltd. It is currently in Phase 1 development. Also known as: PA5108.

At a glance

Generic namePA5108 Latanoprost FA SR Ocular Implant
Also known asPA5108
SponsorPolyActiva Pty Ltd
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PA5108 Latanoprost FA SR Ocular Implant

What is PA5108 Latanoprost FA SR Ocular Implant?

PA5108 Latanoprost FA SR Ocular Implant is a Small molecule drug developed by PolyActiva Pty Ltd.

Who makes PA5108 Latanoprost FA SR Ocular Implant?

PA5108 Latanoprost FA SR Ocular Implant is developed by PolyActiva Pty Ltd (see full PolyActiva Pty Ltd pipeline at /company/polyactiva-pty-ltd).

Is PA5108 Latanoprost FA SR Ocular Implant also known as anything else?

PA5108 Latanoprost FA SR Ocular Implant is also known as PA5108.

What development phase is PA5108 Latanoprost FA SR Ocular Implant in?

PA5108 Latanoprost FA SR Ocular Implant is in Phase 1.

Related